Table 2.
Patient characteristics at NA discontinuation and outcomes in relation to the detectability of pgRNA at EOT
| Total N = 74 |
pgRNA positive N = 7 |
pgRNA negative N = 67 |
p value | |
|---|---|---|---|---|
| Patient characteristics at NA discontinuation | ||||
| Age, years | 60 (27–83) | 64 (43–73) | 60 (27–83) | 0.561 |
| Sex, females/males | 19/55 | 2/5 | 17/50 | 0.855 |
| NA genetic barrier, high/low | 14/60 | 7/0 | 53/14 | 0.179 |
| Duration of NA treatment, months | 75 (36–220) | 94 (36–167) | 74 (36–220) | 0.183 |
| ALT, IU/L | 21 (10–40) | 23 (12–40) | 21 (10–40) | 0.432 |
| HBsAg, log10 IU/mL | 2.48 (ND–4.59) | 2.73 (2.03–3.77) | 2.3 (ND–4.59) | 0.297 |
| Outcomes after NA discontinuation | ||||
| Virological relapse, n (%) | 42 (57) | 7 (100%) | 35 (52%) | 0.016 |
| Clinical relapse, n (%) | 21 (28) | 5 (71%) | 17 (25%) | 0.011 |
| Retreatment, n (%) | 14 (19) | 5 (71%) | 9 (13%) | < 0.01 |
| HBsAg loss, n (%) | 33 (45) | 0 | 33 (49%) | 0.013 |
Quantitative variables are presented as median (min–max) values, in bold statistically significant values (p < 0.05) are shown
NA, nucleos(t)ide analogue; ND, not detectable